The Archer® FusionPlex Lung panel is a targeted next-generation sequencing (NGS) product to detect EGFR vIII and MET exon 14 skipping events along with prominent ALK, BRAF, FGFR, NRG1, NTRK, RET, and ROS1 fusions and select point mutations in 14 key gene targets associated with lung cancer. The panel is powered by Archer’s proprietary Anchored Multiplex PCR (AMP™) target enrichment chemistry to detect fusions in a single sequencing product, even without prior knowledge of fusion partners or breakpoints.
Comprehensive Fusion Detection
AMP chemistry utilizes open-ended targeted amplification to identify gene fusions whether or not the fusion partner is known.
Detect cancer-associated isoforms and alternative splicing events.
Purpose-built for wide sample type compatibility, including low-input and degraded samples such as FFPE tissue.
Simple, Lyophilized Workflow
Easy-to-handle lyophilized reagents and a simple workflow to minimize errors and reduce turn-around time.
Input Nucleic Acid Required*
Unique Molecular On-Target %
Fresh frozen and FFPE
Illumina® and Ion Torrent™
Input recommendations for FFPE samples vary depending on Archer PreSeq® RNA QC score; 50ng input recommended in absence of PreSeq screening